AIV Specific Neutra™ Antibody Products
Product listAccelerate Your Research and Development!
Are you currently facing challenges in the accurate detection, precise quantification, or comprehensive study of Avian Influenza Virus (AIV) in complex biological and environmental samples? Creative Biolabs’ AIV Specific Antibody Products help you achieve unparalleled precision and reliability in your avian influenza research, enabling robust surveillance, diagnostic development, and fundamental studies into viral pathogenesis through advanced immunoassay tools and high-specificity antibodies.
Contact our team to get an inquiry now!
Introduction of AIV
Avian influenza, commonly known as bird flu, is a highly contagious viral disease caused by Avian Influenza Virus (AIV). These viruses primarily infect wild aquatic birds, which serve as natural reservoirs, and can spread to domestic poultry and, in rare instances, to other mammals and humans. AIVs are categorized by surface glycoproteins—hemagglutinin (HA) and neuraminidase (NA)—defining subtypes. Eighteen HA (H1-H18) and eleven NA (N1-N11) designations exist.
Fig. 1 Avian influenza virus illustrating its various components.1
AIV transmission primarily occurs through direct bird-to-bird contact or indirectly via contaminated environments, including feces, nasal secretions, and contaminated equipment, feed, or water. The virus can persist in the environment, making biosecurity measures crucial for prevention.
Human infections with AIV are sporadic and usually result from close and prolonged contact with infected poultry or contaminated environments. Although human-to-human transmission has been rare and limited, the potential for AIVs to adapt and cause pandemics remains a significant public health concern. Recent outbreaks, such as the H5N1 virus detected in dairy cattle herds in the United States in March 2024, highlight the evolving nature of AIV and its potential to cross species barriers, impacting livestock and posing new risks to farm workers. Clinical signs in humans can range from mild respiratory symptoms to severe pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure, and even death. Understanding the intricate structure, function, and transmission dynamics of AIV is fundamental for developing effective diagnostic, prophylactic, and therapeutic strategies.
Fig. 2 Pathogenesis of H5N1 virus infection.1
Antibodies Against AIV
Antibodies specifically targeting AIV are indispensable tools for research, diagnostics, and surveillance efforts aimed at controlling and preventing the spread of this significant pathogen. These antibodies are developed to bind with high affinity and specificity to various AIV components, enabling their precise detection and characterization in diverse biological samples.
Key applications of AIV-specific antibodies include:
- Antigen Detection: Antibodies against key viral proteins, such as Hemagglutinin (HA) and Neuraminidase (NA), are widely used in immunoassays like ELISA and Western Blotting to detect the presence of AIV antigens in infected tissues, environmental samples, and cell cultures. The HA protein, for instance, is critical for viral entry into host cells, making antibodies against it valuable for identifying viral presence and subtype.
- Serological Surveillance: AIV antibodies are crucial for detecting host immune responses to the virus. Serological assays using specific antibodies can identify infected animals or humans by detecting anti-AIV antibodies in serum, indicating past or current exposure. This is essential for epidemiological research and tracking herd immunity.
- Immunohistochemistry (IHC) and Immunofluorescence (IF): These techniques utilize AIV-specific antibodies to visualize viral antigens within infected cells or tissues, providing insights into viral tropism, replication sites, and pathological changes at a cellular level.
- Viral Neutralization Assays: Certain antibodies can neutralize the infectivity of AIV by blocking viral attachment or entry into host cells. These neutralizing antibodies are critical for assessing vaccine efficacy and identifying potential therapeutic candidates.
- Vaccine Development and Evaluation: Antibodies are used to quantify viral antigens in vaccine preparations and to evaluate the immune response elicited by vaccine candidates in animal models, ensuring vaccine potency and effectiveness.
Why Choose Us?
Creative Biolabs’ AIV Specific Antibody Products are meticulously engineered to provide targeted solutions for the multifaceted challenges in avian influenza research and diagnostics. Our antibodies deliver specific deliverables and problem-solving capabilities crucial for advancing your projects:
- Enhanced Detection Sensitivity: Our antibodies are optimized for high sensitivity, enabling the detection of even low concentrations of AIV antigens in various matrices, which is critical for early detection and surveillance efforts in poultry, wild birds, and other susceptible hosts, including mammals.
- Superior Specificity: Rigorous validation ensures minimal cross-reactivity with other influenza strains or non-target proteins, providing highly accurate and reliable results, reducing false positives, and increasing confidence in your data.
- Versatile Application Compatibility: Designed for broad utility, our antibodies are suitable for a wide array of immunoassay formats, including Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Immunofluorescence (IF), Immunohistochemistry (IHC), and flow cytometry, offering flexibility for diverse research needs.
- Support for Diagnostic Development: Our high-quality antibodies serve as essential reagents for the development and optimization of rapid, reliable diagnostic kits for AIV, supporting disease control and outbreak management.
- Facilitating Pathogenesis Studies: By enabling precise detection and localization of viral proteins, our antibodies are invaluable tools for investigating viral replication, host-pathogen interactions, and the molecular mechanisms underlying AIV pathogenesis.
- Advancing Surveillance and Epidemiology: Accurate detection tools are paramount for effective surveillance programs, helping to track viral spread, identify emerging strains, and inform public health strategies.
FAQs
Q: How do the antibody products ensure high specificity for avian influenza viruses, given the diversity of influenza strains?
A: Our antibody products undergo extensive validation, including rigorous cross-reactivity testing against a wide panel of influenza A and B strains, as well as other common respiratory pathogens. This meticulous screening process, combined with advanced immunization and selection strategies, ensures that the antibodies exhibit high affinity and specificity for target AIV antigens, minimizing non-specific binding and false positives.
Q: What are the primary applications for these AIV antibody products in a research laboratory setting?
A: These antibody products are highly versatile for various research applications. They are commonly used in ELISA for antigen detection and serological surveillance, Western Blotting for protein identification, Immunofluorescence and Immunohistochemistry for viral localization in cells and tissues, and flow cytometry for analyzing infected cell populations. They are invaluable for studying viral replication, pathogenesis, host immune responses, and evaluating antiviral compounds.
Q: Can these antibodies be used for the detection of both highly pathogenic and low pathogenic avian influenza strains?
A: Yes, our antibody products are designed to detect conserved viral antigens that are present across both highly pathogenic (HPAI) and low pathogenic (LPAI) avian influenza strains, depending on the specific antibody target. For critical applications requiring differentiation, we also offer subtype-specific antibodies (e.g., H5-specific, N1-specific) to enable precise identification of particular AIV subtypes.
Q: What are the typical sample types that can be analyzed using these antibody products?
A: Our AIV antibody products are validated for use with a wide range of sample types relevant to avian influenza research and diagnostics. These include, but are not limited to, tracheal and cloacal swabs, tissue homogenates (e.g., lung, spleen), serum, plasma, and cell culture supernatants. Proper sample preparation protocols are crucial for optimal performance, and detailed guidelines are provided with each product.
Q: How do these antibody-based detection methods compare to nucleic acid-based detection methods (e.g., PCR) for AIV?
A: Antibody-based detection methods, such as immunoassays, offer distinct advantages, particularly for rapid, high-throughput screening and antigen detection. While nucleic acid-based methods (like RT-PCR) are highly sensitive for detecting viral genetic material, antibody-based assays provide direct evidence of viral protein presence, which can be crucial for assessing active infection or viral load. Combining both approaches often provides a comprehensive diagnostic picture, leveraging the strengths of each method.
Access the Creative Biolabs Edge – Request Your Quote Now
REFERENCE
- Dey, Piyush et al. “Immune Control of Avian Influenza Virus Infection and Its Vaccine Development.” Vaccines vol. 11,3 593. 4 Mar. 2023, DOI:10.3390/vaccines11030593. Distributed under Open Access license CC BY 4.0, without modification.
